Toni C. Strong, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2501 Capehart Rd, Ste 1116, Offutt A F B, NE 68113 Phone: 402-294-5712 Fax: 402-294-9250 |
Dalton Phillip Wilson, DENTIST Dentist - Prosthodontics Medicare: Not Enrolled in Medicare Practice Location: 2501 Capehart Rd, 55 Medical Group, Offutt A F B, NE 68113 Phone: 402-232-9208 Fax: 402-294-9250 |
Neil Dunlow Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 2501 Capehart Rd, Offutt A F B, NE 68113 Phone: 402-294-9251 |
Dr. Stephen A Schmidt, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2501 Capehart Rd, Ste 1i16, Offutt A F B, NE 68113 Phone: 402-294-8021 Fax: 402-294-9250 |
Dr. Jeffrey Grant Larkin, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 2501 Capehart Rd, Offutt A F B, NE 68113 Phone: 402-294-3212 |
Dr. Daniel Joseph Binkowski, DDS, PHD Dentist Medicare: Not Enrolled in Medicare Practice Location: 2501 Capehart Rd, Offutt A F B, NE 68113 Phone: 402-232-0620 |
Dr. Vincent John Takacs, DDS Dentist - Periodontics Medicare: Not Enrolled in Medicare Practice Location: 2501 Capehart Rd, Ste1i16 Offutt Afb, Offutt A F B, NE 68113 Phone: 402-232-9183 Fax: 402-294-9250 |
News Archive
According to a new study from the Slone Epidemiology Center (SEC) at Boston University, African-American women who reported sexual or physical abuse before age 11 had a greater risk of uterine fibroids in adulthood compared with women who had no such abuse history.
A $7.25 million gift to Weill Medical College of Cornell University will establish the Abby and Howard P. Milstein Chemistry Core Facility and the Abby and Howard P. Milstein Program in Chemical Biology.
According to the manufacturers, a simple DIY test can tell drinkers how much damage has been done to their livers.
A paper in the current issue of Psychotherapy and Psychosomatics by Giovanni Fava, MD (University of Bologna) provides a critical review of the data concerned with antidepressant drugs.
Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.
› Verified 2 days ago